Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 6,190 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly conducts its businesses within domestic and overseas markets.
01801.HK stock price ended at $89.05 on jeudi, after dropping 0.67%
On the latest trading day Feb 12, 2026, the stock price of 01801.HK fell by 0.67%, dropping from $89.50 to $89.05. During the session, the stock saw a volatility of 3.53%, with prices oscillating between a daily low of $87.75 and a high of $90.85. On the latest trading day, the trading volume for 01801.HK rose by 1.2M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 10.1M shares were traded, with a market value of approximately $153.2B.
Signaux Techniques de 01801.HK
Résumé des Signaux Techniques
Acheter des signaux 2
Signaux neutres 1
Signaux de vente 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
01801.HK présente actuellement 2 signaux d'achat et 4 signaux de vente. L'action est en Tendance baissière depuis 12:00 AM, avec une variation totale du prix de -0.67% pendant cette période. En général, les indicateurs techniques indiquent une tendance Sell à moyen terme.
Signaux haussiers/baissiers pour 01801.HK
Nous analysons les indicateurs clés comme les moyennes mobiles, le RSI, le MACD et le volume de transactions pour générer des signaux haussiers et baissiers pour 01801.HK, vous aidant à prendre des décisions d'investissement éclairées.